At a crossroads in oncology.
We survey the current paradigm for cancer therapy and offer a perspective on the state of clinical oncology. Next, we address the key clinical and biological obstacles that have hampered progress to date. Recent insights into the true genetic complexity of cancer, the mixed clinical performance of targeted therapies, and the homogeneity of industry pipelines argue for new approaches to cancer therapy.
Kamb
Alexander
A
Amgen, Inc., 1120 Veterans Blvd, South San Francisco, CA 94080, USA. akamb@amgen.com
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D035843:Biomedical Research; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D055808:Drug Discovery; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy
D000970:Antineoplastic Agents